Predictors of Survival in Patients With Bone Metastasis of Lung Cancer

[1]  M. Nishimura,et al.  Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer , 2007, BMC Cancer.

[2]  K. Arimura,et al.  [Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years]. , 2006, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

[3]  N. Ishikawa,et al.  Long-term survival cases of lung cancer presented as solitary bone metastasis. , 2005, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[4]  N. Hanna,et al.  Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. , 2005, Clinical lung cancer.

[5]  H. Sugiura,et al.  Prognostic factors and a scoring system for patients with skeletal metastasis. , 2005, The Journal of bone and joint surgery. British volume.

[6]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Marijnen,et al.  Prediction of survival in patients with metastases in the spinal column , 2005, Cancer.

[8]  S. Skjeldal,et al.  The Scandinavian Sarcoma Group skeletal metastasis registerSurvival after surgery for bone metastases in the pelvis and extremities , 2004, Acta orthopaedica Scandinavica. Supplementum.

[9]  H. Baba,et al.  Total en bloc spondylectomy for solitary spinal metastases , 1994, International Orthopaedics.

[10]  M. Ebina,et al.  Severe acute interstitial pneumonia and gefitinib , 2003, The Lancet.

[11]  Roy S Herbst,et al.  Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Tomita,et al.  Surgical Strategy for Spinal Metastases , 2001, Spine.

[13]  H. Saka,et al.  Prognostic Factors for Short‐term Survival in Patients with Stage IV Non‐small Cell Lung Cancer , 1999, Japanese journal of cancer research : Gann.

[14]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[15]  Y. Tokuhashi,et al.  Scoring System for the Preoperative Evaluation of Metastatic Spine Tumor Prognosis , 1990, Spine.

[16]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[17]  K E Stanley,et al.  Prognostic factors for survival in patients with inoperable lung cancer. , 1980, Journal of the National Cancer Institute.

[18]  G. Freise,et al.  Bronchial carcinoma and long-term survival. Retrospective study of 433 patients who underwent resection. , 1978, Thorax.

[19]  M. Francis,et al.  Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  A. Johnston.  Pathology of Metastatic Tumors in Bone , 1970, Clinical orthopaedics and related research.

[21]  O. V. Batson.  THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES , 1940, Annals of surgery.